|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
Batty GD, Kivimaki M, Morrison D, et al:
Risk factors for pancreatic cancer mortality: extended follow-up of
the original Whitehall Study. Cancer Epidemiol Biomarkers Prev.
18:673–675. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Landi S: Genetic predisposition and
environmental risk factors to pancreatic cancer: A review of the
literature. Mutat Res. 681:299–307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lowenfels AB and Maisonneuve P:
Epidemiology and risk factors for pancreatic cancer. Best Pract Res
Clin Gastroenterol. 20:197–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Genkinger JM, Spiegelman D, Anderson KE,
et al: Alcohol intake and pancreatic cancer risk: a pooled analysis
of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev.
18:765–776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan MM, Bondy ML, Wolff RA, et al: Risk
factors for pancreatic cancer: case-control study. Am J
Gastroenterol. 102:2696–2707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peek RM Jr and Crabtree JE: Helicobacter
infection and gastric neoplasia. J Pathol. 208:233–248. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Canavan C, Abrams KR and Mayberry J:
Meta-analysis: colorectal and small bowel cancer risk in patients
with Crohn’s disease. Aliment Pharmacol Ther. 23:1097–1104.
2006.
|
|
10
|
Solaymani-Dodaran M, Logan RF, West J,
Card T and Coupland C: Risk of oesophageal cancer in Barrett’s
oesophagus and gastro-oesophageal reflux. Gut. 53:1070–1074.
2004.
|
|
11
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar
|
|
12
|
Ekbom A, McLaughlin JK, Karlsson BM, et
al: Pancreatitis and pancreatic cancer: a population-based study. J
Natl Cancer Inst. 86:625–627. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Talamini G, Falconi M, Bassi C, et al:
Incidence of cancer in the course of chronic pancreatitis. Am J
Gastroenterol. 94:1253–1260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lowenfels AB, Maisonneuve P, Cavallini G,
et al: Pancreatitis and the risk of pancreatic cancer.
International Pancreatitis Study Group. N Engl J Med.
328:1433–1437. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maisonneuve P, Lowenfels AB, Müllhaupt B,
et al: Cigarette smoking accelerates progression of alcoholic
chronic pancreatitis. Gut. 54:510–514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Doll R, Peto R, Hall E, Wheatley K and
Gray R: Mortality in relation to consumption of alcohol: 13 years’
observations on male British doctors. BMJ. 309:911–918. 1994.
|
|
17
|
Bracci PM, Wang F, Hassan MM, Gupta S, Li
D and Holly EA: Pancreatitis and pancreatic cancer in two large
pooled case-control studies. Cancer Causes Control. 20:1723–1731.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bansal P and Sonnenberg A: Pancreatitis is
a risk factor for pancreatic cancer. Gastroenterology. 109:247–251.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lowenfels AB, Maisonneuve P, DiMagno EP,
Elitsur Y, Gates LK Jr, Perrault J and Whitcomb DC: Hereditary
pancreatitis and the risk of pancreatic cancer. International
Hereditary Pancreatitis Study Group. J Natl Cancer Inst.
89:442–446. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chari ST, Mohan V, Pitchumoni CS,
Viswanathan M, Madanagopalan N and Lowenfels AB: Risk of pancreatic
carcinoma in tropical calcifying pancreatitis: an epidemiologic
study. Pancreas. 9:62–66. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji B, Tsou L, Wang H, Gaiser S, et al: Ras
activity levels control the development of pancreatic diseases.
Gastroenterology. 137:1072–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Z, Ali S, Banerjee S, et al:
Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of
pancreatic cancer by induction of EMT consistent with cancer stem
cell phenotype. J Cell Physiol. 228:556–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bishop M, Xenoulis P and Steiner JM:
Association between this SPINK1 variant and clinically detectable
pancreatitis. J Vet Intern Med. 27:427–428. 2013.PubMed/NCBI
|
|
24
|
Hucl T, Jesnowski R, Pfützer RH, Elsässer
HP and Löhr M: SPINK1 variants in young-onset pancreatic cancer. J
Gastroenterol. 42:5992007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schlosser W, Schlosser S, Ramadani M,
Gansauge F, Gansauge S and Beger HG: Cyclooxygenase-2 is
overexpressed in chronic pancreatitis. Pancreas. 25:26–30. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vinokurova LV, Berezina OI, Drozdov VN,
Petrakov AV and Nilova TV: Nitric oxide and indicators of oxidative
stress in patients with exacerbation of chronic pancreatitis. Eksp
Klin Gastroenterol. 2:75–81. 2011.(In Russian).
|
|
27
|
Bernards A and Settleman J: GAP control:
regulating the regulators of small GTPases. Trends Cell Biol.
14:377–385. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Voice JK, Klemke RL, Le A and Jackson JH:
Four human ras homologs differ in their abilities to activate
Raf-1, induce transformation, and stimulate cell motility. J Biol
Chem. 274:17164–17170. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maekawa M, Nishida E and Tanoue T:
Identification of the anti-proliferative protein Tob as a MAPK
substrate. J Biol Chem. 277:37783–37787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roux PP, Ballif BA, Anjum R, Gygi SP and
Blenis J: Tumor-promoting phorbol esters and activated Ras
inactivate the tuberous sclerosis tumor suppressor complex via p90
ribosomal S6 kinase. Proc Natl Acad Sci USA. 101:13489–13494. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rodriguez-Viciana P, Warne PH,
Vanhaesebroeck B, Waterfield MD and Downward J: Activation of
phosphoinositide 3-kinase by interaction with Ras and by point
mutation. EMBO J. 15:2442–2451. 1996.PubMed/NCBI
|
|
32
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
33
|
Rodriguez-Viciana P, Warne PH, Khwaja A,
et al: Role of phosphoinositide 3-OH kinase in cell transformation
and control of the actin cytoskeleton by Ras. Cell. 89:457–467.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mulligan NJ, Yang S, Andry C, Klein M and
O’Brien MJ: The role of p21ras in pancreatic neoplasia and chronic
pancreatitis. Hum Pathol. 30:602–610. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mu DQ, Peng YS and Xu QJ: Values of
mutations of K-ras oncogene at codon 12 in detection of pancreatic
cancer: 15-year experience. World J Gastroenterol. 10:471–475.
2004.PubMed/NCBI
|
|
36
|
Guerra C, Schuhmacher AJ, Cañamero M, et
al: Chronic pancreatitis is essential for induction of pancreatic
ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer
Cell. 11:291–302. 2007. View Article : Google Scholar
|
|
37
|
Logsdon CD and Ji B: Ras activity in
acinar cells links chronic pancreatitis and pancreatic cancer. Clin
Gastroenterol Hepatol. 7(11 Suppl): S40–S43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guerra C, Collado M, Navas C, et al:
Pancreatitis-induced inflammation contributes to pancreatic cancer
by inhibiting oncogene-induced senescence. Cancer Cell. 19:728–739.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Collado M and Serrano M: Senescence in
tumours: evidence from mice and humans. Nat Rev Cancer. 10:51–57.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Navas C, Hernández-Porras I, Schuhmacher
AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is
essential for k-ras oncogene-driven pancreatic ductal
adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ardito CM, Grüner BM, Takeuchi KK, et al:
EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
Cancer Cell. 22:304–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, Banerjee S, Ahmad A, et al:
Activated K-ras and INK4a/Arf deficiency cooperate during the
development of pancreatic cancer by activation of Notch and NF-κB
signaling pathways. PLoS One. 6:e205372011.PubMed/NCBI
|
|
43
|
Daniluk J, Liu Y, Deng D, et al: An NF-κB
pathway-mediated positive feedback loop amplifies Ras activity to
pathological levels in mice. J Clin Invest. 122:1519–1528.
2012.
|
|
44
|
Friday BB and Adjei AA: K-ras as a target
for cancer therapy. Biochim Biophys Acta. 1756:127–144.
2005.PubMed/NCBI
|
|
45
|
Kamisawa T, Takuma K, Tabata T, Egawa N
and Yamaguchi T: Long-term follow-up of chronic pancreatitis
patients with K-ras mutation in the pancreatic juice.
Hepatogastroenterology. 58:174–176. 2011.PubMed/NCBI
|
|
46
|
Prescott SM and Fitzpatrick FA:
Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta.
1470:M69–M78. 2000.PubMed/NCBI
|
|
47
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Diaz A, Chepenik KP, Korn JH, Reginato AM
and Jimenez SA: Differential regulation of cyclooxygenases 1 and 2
by interleukin-1 beta, tumor necrosis factor-alpha, and
transforming growth factor-beta 1 in human lung fibroblasts. Exp
Cell Res. 241:222–229. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aoki H, Ohnishi H, Hama K, et al:
Cyclooxygenase-2 is required for activated pancreatic stellate
cells to respond to proinflammatory cytokines. Am J Physiol Cell
Physiol. 292:C259–C268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Koliopanos A, Friess H, Kleeff J, Roggo A,
Zimmermann A and Büchler MW: Cyclooxygenase 2 expression in chronic
pancreatitis: correlation with stage of the disease and diabetes
mellitus. Digestion. 64:240–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
O’Brien G, Shields CJ, Winter DC, Dillon
JP, Kirwan WO and Redmond HP: Cyclooxygenase-2 plays a central role
in the genesis of pancreatitis and associated lung injury.
Hepatobiliary Pancreat Dis Int. 4:126–129. 2005.PubMed/NCBI
|
|
52
|
Albazaz R, Verbeke CS, Rahman SH and
McMahon MJ: Cyclooxygenase-2 expression associated with severity of
PanIN lesions: a possible link between chronic pancreatitis and
pancreatic cancer. Pancreatology. 5:361–369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Niijima M, Yamaguchi T, Ishihara T, Hara
T, Kato K, Kondo F and Saisho H: Immunohistochemical analysis and
in situ hybridization of cyclooxygenase-2 expression in intraductal
papillary-mucinous tumors of the pancreas. Cancer. 94:1565–1573.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.PubMed/NCBI
|
|
55
|
Kokawa A, Kondo H, Gotoda T, et al:
Increased expression of cyclooxygenase-2 in human pancreatic
neoplasms and potential for chemoprevention by cyclooxygenase
inhibitors. Cancer. 91:333–338. 2001. View Article : Google Scholar
|
|
56
|
Hillion J, Smail SS, Di Cello F, et al:
The HMGA1-COX-2 axis: a key molecular pathway and potential target
in pancreatic adenocarcinoma. Pancreatology. 12:372–379. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kirane A, Toombs JE, Ostapoff K, et al:
Apricoxib, a novel inhibitor of COX-2, markedly improves standard
therapy response in molecularly defined models of pancreatic
cancer. Clin Cancer Res. 18:5031–5042. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kong G, Kim EK, Kim WS, et al: Role of
cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic
cancer. J Gastroenterol Hepatol. 17:914–921. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ding XZ, Tong WG and Adrian TE: Blockade
of cyclooxygenase-2 inhibits proliferation and induces apoptosis in
human pancreatic cancer cells. Anticancer Res. 20:2625–2631.
2000.PubMed/NCBI
|
|
60
|
Eibl G, Bruemmer D, Okada Y, et al: PGE(2)
is generated by specific COX-2 activity and increases VEGF
production in COX-2-expressing human pancreatic cancer cells.
Biochem Biophys Res Commun. 306:887–897. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Colby JK, Klein RD, McArthur MJ, et al:
Progressive metaplastic and dysplastic changes in mouse pancreas
induced by cyclooxygenase-2 overexpression. Neoplasia. 10:782–796.
2008.PubMed/NCBI
|
|
62
|
Furukawa F, Nishikawa A, Lee IS, et al: A
cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation
phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic
carcinogenesis in hamsters. Int J Cancer. 104:269–273. 2003.
View Article : Google Scholar
|
|
63
|
Anderson KE, Johnson TW, Lazovich D and
Folsom AR: Association between nonsteroidal anti-inflammatory drug
use and the incidence of pancreatic cancer. J Natl Cancer Inst.
94:1168–1171. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wenger FA, Kilian M, Achucarro P, et al:
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in
Syrian hamsters. Pancreatology. 2:54–60. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
|
|
66
|
Jacobs EJ, Connell CJ, Rodriguez C, et al:
Aspirin use and pancreatic cancer mortality in a large United
States cohort. J Natl Cancer Inst. 96:524–528. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schernhammer ES, Kang JH, Chan AT, et al:
A prospective study of aspirin use and the risk of pancreatic
cancer in women. J Natl Cancer Inst. 96:22–28. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yamamoto Y and Gaynor RB: Therapeutic
potential of inhibition of the NF-kappaB pathway in the treatment
of inflammation and cancer. J Clin Invest. 107:135–142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shi Q, Le X, Abbruzzese JL, et al:
Cooperation between transcription factor AP-1 and NF-kappaB in the
induction of interleukin-8 in human pancreatic adenocarcinoma cells
by hypoxia. J Interferon Cytokine Res. 19:1363–1371. 1999.
View Article : Google Scholar
|
|
70
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: from innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
71
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lu Z, Li Y, Takwi A, et al: miR-301a as an
NF-κB activator in pancreatic cancer cells. EMBO J. 30:57–67.
2011.
|
|
73
|
Liptay S, Weber CK, Ludwig L, et al:
Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel
activity in pancreatic cancer. Int J Cancer. 105:735–746. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fujioka S, Sclabas GM, Schmidt C, et al:
Function of nuclear factor kappaB in pancreatic cancer metastasis.
Clin Cancer Res. 9:346–354. 2003.PubMed/NCBI
|
|
75
|
Hoffmann A and Baltimore D: Circuitry of
nuclear factor kappaB signaling. Immunol Rev. 210:171–186. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Qing G and Xiao G: Essential role of
IkappaB kinase alpha in the constitutive processing of NF-kappaB2
p100. J Biol Chem. 280:9765–9768. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Carbone C and Melisi D: NF-κB as a target
for pancreatic cancer therapy. Expert Opin Ther Targets. 16(Suppl
2): S1–S10. 2012.
|
|
78
|
Niu J, Li Z, Peng B and Chiao PJ:
Identification of an autoregulatory feedback pathway involving
interleukin-1alpha in induction of constitutive NF-kappaB
activation in pancreatic cancer cells. J Biol Chem.
279:16452–16462. 2004. View Article : Google Scholar
|
|
79
|
Melisi D, Niu J, Chang Z, et al: Secreted
interleukin-1alpha induces a metastatic phenotype in pancreatic
cancer by sustaining a constitutive activation of nuclear
factor-kappaB. Mol Cancer Res. 7:624–633. 2009. View Article : Google Scholar
|
|
80
|
Barbie DA, Tamayo P, Boehm JS, et al:
Systematic RNA interference reveals that oncogenic KRAS-driven
cancers require TBK1. Nature. 462:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kazal LA, Spicer DS and Brahinsky RA:
Isolation of a crystalline trypsin inhibitor-anticoagulant protein
from pancreas. J Am Chem Soc. 70:3034–3040. 1948. View Article : Google Scholar
|
|
82
|
Witt H, Luck W, Hennies HC, et al:
Mutations in the gene encoding the serine protease inhibitor, Kazal
type 1 are associated with chronic pancreatitis. Nat Genet.
25:213–216. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
83
|
Schneider A, Barmada MM, Slivka A, Martin
JA and Whitcomb DC: Clinical characterization of patients with
idiopathic chronic pancreatitis and SPINK1 mutations. Scand J
Gastroenterol. 39:903–904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chen JM, Mercier B, Audrezet MP, et al:
Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene
in idiopathic chronic pancreatitis. Gastroenterology.
120:1061–1064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pfützer RH, Barmada MM, Brunskill AP, et
al: SPINK1/PSTI polymorphisms act as disease modifiers in familial
and idiopathic chronic pancreatitis. Gastroenterology. 119:615–623.
2000.PubMed/NCBI
|
|
86
|
Kuwata K, Hirota M, Nishimori I, Otsuki M
and Ogawa M: Mutational analysis of the pancreatic secretory
trypsin inhibitor gene in familial and juvenile pancreatitis in
Japan. J Gastroenterol. 38:365–370. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ohmuraya M, Hirota M, Araki M, et al:
Autophagic cell death of pancreatic acinar cells in serine protease
inhibitor Kazal type 3-deficient mice. Gastroenterology.
129:696–705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rebours V, Couvelard A, Sauvanet A, et al:
Pancreatic intraepithelial neoplasia is associated with chronic
pancreatitis due to serine protease inhibitor kazal type 1 and
cystic fibrosis transmembrane conductance regulator mutations.
Pancreas. 39:947–948. 2010. View Article : Google Scholar
|
|
89
|
Shimosegawa T, Kume K and Satoh K: Chronic
pancreatitis and pancreatic cancer: prediction and mechanism. Clin
Gastroenterol Hepatol. 7(11 Suppl): S23–S28. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ogawa M, Matsuura N, Higashiyama K and
Mori T: Expression of pancreatic secretory trypsin inhibitor in
various cancer cells. Res Commun Chem Pathol Pharmacol. 55:137–140.
1987.PubMed/NCBI
|
|
91
|
Ozaki N, Ohmuraya M, Hirota M, et al:
Serine protease inhibitor Kazal type 1 promotes proliferation of
pancreatic cancer cells through the epidermal growth factor
receptor. Mol Cancer Res. 7:1572–1581. 2009. View Article : Google Scholar
|
|
92
|
Ozaki N, Ohmuraya M, Ida S, et al: Serine
protease inhibitor Kazal type 1 and epidermal growth factor
receptor are expressed in pancreatic tubular adenocarcinoma,
intraductal papillary mucinous neoplasm, and pancreatic
intraepithelial neoplasia. J Hepatobiliary Pancreat Sci. Mar
12–2013.(Epub ahead of print).
|
|
93
|
Oikawa T, Hitomi J, Kono A, et al:
Frequent expression of genes for receptor tyrosine kinases and
their ligands in human pancreatic cancer cells. Int J Pancreatol.
18:15–23. 1995.PubMed/NCBI
|
|
94
|
Korc M, Friess H, Yamanaka Y, et al:
Chronic pancreatitis is associated with increased concentrations of
epidermal growth factor receptor, transforming growth factor alpha,
and phospholipase C gamma. Gut. 35:1468–1473. 1994. View Article : Google Scholar
|
|
95
|
Tonouchi A, Ohtsuka M, Ito H, et al:
Relationship between pancreatic secretory trypsin inhibitor and
early recurrence of intrahepatic cholangiocarcinoma following
surgical resection. Am J Gastroenterol. 101:1601–1610. 2006.
View Article : Google Scholar
|
|
96
|
Gouyer V, Fontaine D, Dumont P, et al:
Autocrine induction of invasion and metastasis by tumor-associated
trypsin inhibitor in human colon cancer cells. Oncogene.
27:4024–4033. 2008. View Article : Google Scholar
|
|
97
|
Lo YY and Cruz TF: Involvement of reactive
oxygen species in cytokine and growth factor induction of c-fos
expression in chondrocytes. J Biol Chem. 270:11727–11730. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Liou GY and Storz P: Reactive oxygen
species in cancer. Free Radic Res. 44:479–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
100
|
Leung PS and Chan YC: Role of oxidative
stress in pancreatic inflammation. Antioxid Redox Signal.
11:135–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Garcea G, Dennison AR, Steward WP and
Berry DP: Role of inflammation in pancreatic carcinogenesis and the
implications for future therapy. Pancreatology. 5:514–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lau AT, He QY and Chiu JF: A proteome
analysis of the arsenite response in cultured lung cells: evidence
for in vitro oxidative stress-induced apoptosis. Biochem J.
382:641–650. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Lau AT and Chiu JF: Proteomic and
biochemical analyses of in vitro carcinogen-induced lung cell
transformation: synergism between arsenic and benzo[a]pyrene.
Proteomics. 6:1619–1630. 2006.PubMed/NCBI
|
|
104
|
Barchowsky A, Dudek EJ, Treadwell MD and
Wetterhahn KE: Arsenic induces oxidant stress and NF-kappa B
activation in cultured aortic endothelial cells. Free Radic Biol
Med. 21:783–790. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Schoenberg MH, Birk D and Beger HG:
Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr.
62(6 Suppl): 1306S–1314S. 1995.PubMed/NCBI
|
|
106
|
Kadlubar FF, Anderson KE, Häussermann S,
et al: Comparison of DNA adduct levels associated with oxidative
stress in human pancreas. Mutat Res. 405:125–133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Cullen JJ, Mitros FA and Oberley LW:
Expression of antioxidant enzymes in diseases of the human
pancreas: another link between chronic pancreatitis and pancreatic
cancer. Pancreas. 26:23–27. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Teoh ML, Sun W, Smith BJ, Oberley LW and
Cullen JJ: Modulation of reactive oxygen species in pancreatic
cancer. Clin Cancer Res. 13:7441–7450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Benhar M, Engelberg D and Levitzki A: ROS,
stress-activated kinases and stress signaling in cancer. EMBO Rep.
3:420–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Martindale JL and Holbrook NJ: Cellular
response to oxidative stress: signaling for suicide and survival. J
Cell Physiol. 192:1–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Leonard SS, Harris GK and Shi X:
Metal-induced oxidative stress and signal transduction. Free Radic
Biol Med. 37:1921–1942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Shimojo Y, Akimoto M, Hisanaga T, et al:
Attenuation of reactive oxygen species by antioxidants suppresses
hypoxia-induced epithelial-mesenchymal transition and metastasis of
pancreatic cancer cells. Clin Exp Metastasis. 30:143–154. 2013.
View Article : Google Scholar
|
|
113
|
DeNicola GM, Karreth FA, Humpton TJ, et
al: Oncogene-induced Nrf2 transcription promotes ROS detoxification
and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hossain MZ and Kleve MG: Nickel nanowires
induced and reactive oxygen species mediated apoptosis in human
pancreatic adenocarcinoma cells. Int J Nanomedicine. 6:1475–1485.
2011. View Article : Google Scholar
|
|
115
|
Lau ST, Lin ZX and Leung PS: Role of
reactive oxygen species in brucein D-mediated p38-mitogen-activated
protein kinase and nuclear factor-kappaB signalling pathways in
human pancreatic adenocarcinoma cells. Br J Cancer. 102:583–593.
2010. View Article : Google Scholar
|
|
116
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Inves. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar
|
|
118
|
Wigmore SJ, Fearon KC, Sangster K, Maingay
JP, Garden OJ and Ross JA: Cytokine regulation of constitutive
production of interleukin-8 and -6 by human pancreatic cancer cell
lines and serum cytokine concentrations in patients with pancreatic
cancer. Int J Oncol. 21:881–886. 2002.
|
|
119
|
Talar-Wojnarowska R, Gasiorowska A,
Smolarz B, et al: Clinical significance of interleukin-6 (IL-6)
gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma
and chronic pancreatitis. Dig Dis Sci. 54:683–689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Miron N, Miron MM, Milea VG and Cristea V:
Proinflammatory cytokines: an insight into pancreatic oncogenesis.
Roum Arch Microbiol Immunol. 69:183–189. 2010.PubMed/NCBI
|
|
121
|
Dima SO, Tanase C, Albulescu R, et al: An
exploratory study of inflammatory cytokines as prognostic
biomarkers in patients with ductal pancreatic adenocarcinoma.
Pancreas. 41:1001–1007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Matsuo Y, Takeyama H and Guha S: Cytokine
network: new targeted therapy for pancreatic cancer. Curr Pharm
Des. 18:2416–2419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Maker AV, Katabi N, Qin LX, et al: Cyst
fluid interleukin-1beta (IL1beta) levels predict the risk of
carcinoma in intraductal papillary mucinous neoplasms of the
pancreas. Clin Cancer Res. 17:1502–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: potentiation by inhibition of
NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Beg AA and Baltimore D: An essential role
for NF-kappaB in preventing TNF-alpha-induced cell death. Science.
274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
McDade TP, Perugini RA, Vittimberga FJ Jr,
Carrigan RC and Callery MP: Salicylates inhibit NF-kappaB
activation and enhance TNF-alpha-induced apoptosis in human
pancreatic cancer cells. J Surg Res. 83:56–61. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Baran B, Bechyne I, Siedlar M, et al:
Blood monocytes stimulate migration of human pancreatic carcinoma
cells in vitro: the role of tumour necrosis factor - alpha. Eur J
Cell Biol. 88:743–752. 2009. View Article : Google Scholar
|
|
128
|
Feurino LW, Zhang Y, Bharadwaj U, et al:
IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF
and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther.
6:1096–1100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Block KM, Hanke NT, Maine EA and Baker AF:
IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell
lines. Pancreas. 41:773–781. 2012.PubMed/NCBI
|
|
130
|
Ebrahimi B, Tucker SL, Li D, Abbruzzese JL
and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with
phenotypic characteristics and prognosis. Cancer. 101:2727–2736.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kamohara H, Takahashi M, Ishiko T, Ogawa M
and Baba H: Induction of interleukin-8 (CXCL-8) by tumor necrosis
factor-alpha and leukemia inhibitory factor in pancreatic carcinoma
cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol.
31:627–632. 2007.
|
|
132
|
Hussain F, Wang J, Ahmed R, et al: The
expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas
and pancreatic neuroendocrine tumours. Cytokine. 49:134–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Le X, Shi Q, Wang B, et al: Molecular
regulation of constitutive expression of interleukin-8 in human
pancreatic adenocarcinoma. J Interferon Cytokine Res. 20:935–946.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Xu X, Wang Y, Chen J, et al: High
expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of
pancreatic ductal adenocarcinoma. J Gastrointest Surg.
16:1493–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Grote VA, Kaaks R, Nieters A, et al:
Inflammation marker and risk of pancreatic cancer: a nested
case-control study within the EPIC cohort. Br J Cancer.
106:1866–1874. 2012.PubMed/NCBI
|
|
136
|
Schmieder A, Multhoff G and Radons J:
Interleukin-33 acts as a pro-inflammatory cytokine and modulates
its receptor gene expression in highly metastatic human pancreatic
carcinoma cells. Cytokine. 60:514–521. 2012. View Article : Google Scholar
|
|
137
|
Bonifazi M, Gallus S, Bosetti C, et al:
Aspirin use and pancreatic cancer risk. Eur J Cancer Prev.
19:352–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bradley MC, Hughes CM, Cantwell MM, et al:
Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a
nested case-control study. Br J Cancer. 102:1415–1421. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Rothwell PM, Fowkes FG, Belch JF, et al:
Effect of daily aspirin on long-term risk of death due to cancer:
analysis of individual patient data from randomised trials. Lancet.
377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
